Stryker receives FDA clearance for SAHARA® Lateral 3D

Stryker announced recently the U.S. Food and Drug Administration (FDA) 510(k) clearance of its SAHARA Lateral 3D Expandable Interbody System featuring Lamellar 3D Titanium Technology, which will be on display at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum in Las Vegas, NV.

SAHARA Lateral is the first-ever 3D-printed lateral expandable fusion device and features passive expansion capabilities that are designed to allow surgeons to achieve up to 30 degrees of sagittal spinal correction in skeletally mature patients.

Utilizing a passive expansion mechanism, the implant can either be adjusted from a lateral approach intraoperatively or can adjust passively in a staged posterior approach following osteotomy.

SAHARA Lateral features Lamellar 3D Titanium Technology, which uses an advanced 3D printing method to create structures that were previously difficult or impossible to manufacture using traditional manufacturing techniques. Starting with a titanium powder, the SAHARA implants are grown through the selective application of a high-energy laser beam, incorporating complex internal geometries and a roughened surface architecture.

Previous articleA new pressure equipment certified by BASF
Next articleNew members of the Supervisory Board of thyssenkrupp AG
Stainless Steel World Publisher
Stainless Steel World is part of The KCI Media Group, a group of companies focused on building and sustaining global communities in the flow control industries. We publish news on a daily basis and connect business-to-business professionals through our online communities, publications, conferences and exhibitions.